State stem cell laws now cover eight states, and each one asks something different of your marketing. Six of them require a set notice, word for word, in every stem cell ad. One requires a posted and written notice, and one limits who may advertise at all. This guide shows which states have passed these laws, what each one requires and what none of them change at the federal level.
TLDR: State stem cell laws now cover eight states: Florida, Utah, Tennessee, Vermont, Washington, Georgia, California and Wyoming. Six of them require their own notice, word for word, in every ad. California requires a posted and written notice. Wyoming lets a clinic advertise under its act only if it meets every condition. Arizona’s bill was vetoed. Texas has a narrow investigational framework, and Nevada has no notice law. No state law changes FDA or FTC rules. Read on for what each state requires.
Important Note
This article is for educational purposes only and does not constitute legal advice. State laws governing stem cell practice and marketing are complex, vary significantly by jurisdiction, and are subject to change. Every clinic must consult qualified legal counsel before relying on any state law for marketing decisions. Regen Portal is a marketing and consulting company, not a law firm.
The FDA regulates the products. The FTC regulates the claims. Most clinics stop there, and that is right where the state layer catches them.
Since this guide first ran in May 2026, the map has changed. Florida added a second notice for podiatric physicians on June 11, 2026. Tennessee and Georgia laws took effect on July 1, 2026. We rebuilt this guide in November 2026 around the laws as they stand now.
Here is what you will get. You will see which states have passed stem cell laws and the three kinds of law they use. You will see what each one asks of your ads and your office, and which states people often get wrong. For the exact notice texts, use our state-by-state notice reference.
The Short Answer: Eight States, Three Kinds of Law
Eight states have passed stem cell notice or consent laws. They fall into three groups. Six require a statutory notice in every ad. California requires a posted notice and a written notice. Wyoming sets conditions a clinic must meet before it can advertise under its act.
The table sums up each law. The middle column gives the citation your attorney will want. The last column says what the law asks of your marketing.
| State | Law | What Your Marketing Needs |
|---|---|---|
| Florida (physicians) | s. 458.3245, F.S. | The Florida physician notice in every ad, in type no smaller than the largest type in the ad |
| Florida (podiatric physicians) | s. 461.011, F.S., effective June 11, 2026 | A separate podiatric notice in every ad, same type size rule |
| Utah | Utah Code 58-1-512 | The Utah notice in every ad, a 40-point office posting and a written notice before therapy |
| Tennessee | Public Chapter 1016, effective July 1, 2026 | The Tennessee notice in every ad, same type size rule |
| Vermont | 18 V.S.A. § 4502 | The Vermont notice in every ad, a 40-point office posting and a signed form before each administration |
| Washington | RCW 18.130.420 | The Washington notice in every ad, a 40-point office posting and signed consent for each therapy |
| Georgia | O.C.G.A. § 43-34-49, effective July 1, 2026 | The Georgia notice in every ad, same type size rule |
| California | Business and Professions Code § 684 | A posted notice and a written notice before the first therapy; no ad rule in the statute (our house policy: carry it in ads too) |
| Wyoming | SF 48 | No notice wording; advertise only if the clinic meets every condition of the act |
What this means for your practice: If you practice in one of these eight states, your stem cell marketing carries a state rule on top of the federal rules. If you practice in more than one, you may need more than one notice. Start with the six states that want a notice in every ad.
The Six States That Require a Notice in Every Ad
Florida, Utah, Tennessee, Vermont, Washington and Georgia each wrote a notice into law. Each notice must appear in every ad for the therapy, word for word. The wording is not the same from state to state, so one notice cannot cover all six.
Florida: Physicians and Podiatric Physicians
Florida’s physician law, s. 458.3245, took effect July 1, 2025. It lets Florida physicians use stem cell therapy the FDA has not approved, within their scope of practice, in three fields: orthopedics, wound care and pain management. Osteopathic physicians have a matching section in their own chapter. Products must come from an FDA-registered facility that holds one of the accreditations the law names.
Every ad must carry the Florida notice. It must be clearly legible and no smaller than the largest type in the ad. The patient also signs a consent form before treatment.
Since June 11, 2026, podiatric physicians have their own law, s. 461.011. It covers cellular or tissue-based products used for connective tissue, ligament and tendon repair, wound care or pain management. It has its own notice, with the same type size rule. Our Florida stem cell law deep dive walks through both laws.
Utah
Utah Code 58-1-512 reaches any health care provider whose scope of practice includes stem cell therapy. That is wider than a physician-only law. The provider gives the patient a written notice before the therapy and gets a signed consent form. The notice is also posted at the entrance and in a patient area, on 8.5 by 11 paper in at least 40-point type. And it goes in every ad.
Utah also reaches suppliers. A company may supply cells or tissue products to a Utah provider only after the provider confirms in writing that each patient will get the notice. If you are a manufacturer or distributor, build that step into your Utah account setup.
Tennessee
Tennessee’s Public Chapter 1016 took effect July 1, 2026. It covers stem cell and regenerative medicine therapy within the physician’s scope of practice. It is not limited to orthopedics, pain or wound care. Its notice names “stem cell or regenerative medicine therapies,” so a Tennessee ad cannot borrow another state’s text. Early summaries of this law carried wording that is not in the enacted text, so check any notice you saved before.
Vermont
18 V.S.A. § 4502 covers practitioners who administer “stem cell or stem cell-related products.” Vermont defines that phrase broadly. The definition names sources such as bone marrow, adipose tissue, amniotic membrane and placenta. It also reaches “intracellular or extracellular components or vesicles.”
Vermont wants the notice in every ad and posted in the office in at least 40-point type. The patient signs a disclosure form before each administration, not just the first. The written notice must also tell patients how to file a complaint and how to reach the Attorney General’s Consumer Assistance Program.
Washington
RCW 18.130.420 applies to licensed health professionals who perform a stem cell therapy the FDA has not approved. The notice goes in every ad and on a 40-point posting in the office. The patient signs a consent form before each therapy.
Georgia
Georgia’s law, O.C.G.A. § 43-34-49, took effect July 1, 2026. Its notice speaks of “this physician or his or her designee,” so it reaches the clinicians a physician designates, not only the physician. The notice goes in every ad, under the same type size rule as Florida and Tennessee.
One rule trips up designers more than any other: type size. In Florida, Tennessee and Georgia, the notice must be clearly legible and no smaller than the largest type in the ad. Utah, Vermont and Washington use the same test for print. For other ads, such as radio or video, those three states also accept a notice that is clearly spoken.
What this means for your practice: A state notice is not a disclaimer you write yourself. The state wrote it. Copy it exactly, set it at full size and never edit it to fit a layout. If you practice in Florida, Utah, Tennessee, Vermont, Washington or Georgia, the ad needs your state’s notice word for word.
California: A Posted and Written Notice
California’s stem cell law is Business and Professions Code § 684. It covers health care practitioners who perform a stem cell therapy the FDA has not approved. The statute asks for two things. The notice must be posted at the entrance and in an area patients can see, on 8.5 by 11 paper in at least 40-point type. It must also be given to the patient in writing before the first therapy.
The statute does not mention ads. Our house policy is still to carry the California notice in California ads. It matches what the six notice states require, and it is the careful choice. Just describe it to your team as policy, not as a legal rule.
Watch the wording. California’s notice says the therapies “have not been approved.” There is no “yet” in it. It also says “primary care physician,” not “primary care provider.” A notice copied from Utah or Washington will be wrong in California.
Wyoming: Conditions Before Any Ad
Wyoming’s SF 48 works differently. It has no notice wording at all. Instead, a clinic may advertise stem cell therapy under the act only if it meets every condition of the act.
Those conditions are narrow. The cells must be the patient’s own mesenchymal cells. The therapy needs IRB oversight or investigational status. The cells must be made under current good manufacturing practice. And the patient signs written consent that covers the therapy’s status and the patient’s financial responsibility.
If a Wyoming clinic misses any condition, the ad itself is the problem. Confirm each condition in writing before any Wyoming stem cell ad runs. A house disclosure that tracks the consent terms is a sound extra step. It does not make a non-compliant ad lawful.
Arizona, Texas and Nevada: Not Notice States
Three states come up often in this conversation, and none belongs on the notice list.
Arizona. A 2026 bill would have created a stem cell notice law. It was vetoed, so Arizona has no notice law.
Texas. HB 810, passed in 2017, created an investigational stem cell framework. It is not a clinic authorization, and it is not one of the notice laws above.
Nevada. Nevada is not a stem cell notice state. If a vendor or an old summary tells you otherwise, ask for the statute before you change a single ad.
What No State Law Changes
State stem cell laws sit on top of federal law. They do not replace it. No state law makes a product FDA approved, and no state law shields a false or unsupported claim from the FTC.
Federal enforcement does not wait for a state law. In January 2025, the FTC announced court orders against the co-founders of a stem cell marketing company, in a case it brought with the Georgia Attorney General. The orders ban them from marketing regenerative medicine treatments, stem cell therapy included. They must also pay more than $5.1 million in refunds and civil penalties. That case was filed in 2021. Georgia’s own notice law did not take effect until July 1, 2026.
The FDA has not moved either. Its consumer alert on stem cells and exosomes still warns the public about unapproved products. Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications.
Ad platforms add their own layer. Google Ads does not accept ads that promote stem cell therapy, whatever your state allows. Our post on how FDA warning letters reach clinics covers the federal side in more depth.
What this means for your practice: A state law can let a physician offer a therapy. It cannot make a claim true, and it cannot make a product approved. Every stem cell ad still has to pass federal review first.
A Four-Step State Check Before Any Stem Cell Ad
Run this check every time a stem cell ad, page or post is about to go live. It takes minutes, and it catches the state layer most reviews miss.
- Federal product check. Is the product described accurately, with no claim that it treats, cures or heals a condition? Our guide to how 361 and 351 products differ helps here.
- Federal claims check. Is every claim truthful and supported? Do testimonials and before-and-after images meet FTC rules?
- State notice check. If you practice in Florida, Utah, Tennessee, Vermont, Washington or Georgia, the ad needs your state’s notice word for word, at full size. In California, follow the house policy. In Wyoming, confirm every condition of the act first.
- Multi-state check. If the ad names locations in more than one notice state, ask counsel how to handle each state’s notice. The careful default is to carry each one.
Skipping any one step creates exposure. The notice rules reach every ad, from a social post to a printed flyer.
Frequently Asked Questions
Which States Have Passed Stem Cell Marketing Laws?
Eight states have stem cell notice or consent laws: Florida, Utah, Tennessee, Vermont, Washington, Georgia, California and Wyoming. The first six require a statutory notice in every ad. California requires a posted and written notice. Wyoming lets a clinic advertise under its act only if it meets every condition. Arizona’s 2026 bill was vetoed. Texas has an investigational framework, and Nevada is not a notice state.
Does the Florida Law Apply to Exosomes or Med Spas?
Florida’s two laws name physicians and podiatric physicians, not other license types. Ask counsel how that applies to a med spa’s structure. On products, the physician law defines stem cell therapy by afterbirth placental perinatal stem cells and other cell and tissue products that meet its rules. Its definition leaves out secreted or extracted products. Have counsel confirm whether a given product meets that definition. No state law makes an exosome product FDA approved.
Does the Wyoming Law Cover All Stem Cell Therapies?
No. Wyoming’s SF 48 covers only the patient’s own mesenchymal stem cells, used under IRB oversight or investigational status and made under current good manufacturing practice. The patient must sign written consent. The act has no notice wording, and a clinic may advertise under it only if it meets every condition.
Does a State Stem Cell Law Override Federal FDA or FTC Rules?
No. State law sits on top of federal law. The FDA keeps its authority over the products, and the FTC keeps its authority over the claims. A state law that allows a therapy does not create a federal safe harbor.
What Did the January 2025 FTC Stem Cell Case Show?
It showed that federal enforcement does not depend on a state law. The FTC and the Georgia Attorney General filed the case in 2021, years before Georgia’s notice law. The orders announced in January 2025 ban the co-founders of a stem cell marketing company from marketing regenerative medicine treatments. They must also pay more than $5.1 million in refunds and civil penalties.
What Does California Require?
Business and Professions Code § 684 requires a posted notice at the entrance and in a patient area, on 8.5 by 11 paper in at least 40-point type. The same notice goes to the patient in writing before the first therapy. The statute does not mention ads. Our house policy is to carry the notice in California ads anyway.
Does Utah’s Law Affect Manufacturers and Distributors?
Yes. A company may supply cells or tissue products to a Utah provider only after the provider confirms in writing that each patient will get the Utah notice. Build that written confirmation into your Utah account process.
What If My State Has No Stem Cell Law?
Then federal FDA and FTC rules apply, along with your state’s general consumer protection and medical board rules. No state law also means no state framework to point to. Have counsel review your marketing against the federal rules.
Do State Notice Rules Apply to Digital Ads?
Yes. In the six notice states, treat every promotion of the therapy as an ad: paid social, video, email, print and the web pages that promote it. Ask counsel where your state draws the line. Google Ads does not accept ads that promote stem cell therapy at all, so the notice matters most on the channels where an ad can run.
Key Takeaways
- Eight states have stem cell notice or consent laws: Florida, Utah, Tennessee, Vermont, Washington, Georgia, California and Wyoming.
- Florida, Utah, Tennessee, Vermont, Washington and Georgia require their own notice, word for word, in every ad.
- Florida has two notices. The podiatric one has been in effect since June 11, 2026.
- California requires a posted and written notice. Carrying it in ads is our house policy, not the statute.
- Wyoming has no notice wording. A clinic may advertise under its act only if it meets every condition.
- Arizona’s bill was vetoed. Texas has an investigational framework. Nevada is not a notice state.
- Utah’s law also reaches suppliers. They need written confirmation from the provider before they supply cells or tissue products.
- No state law changes FDA or FTC rules, and Google Ads does not accept ads that promote stem cell therapy.
Need a Compliance-Aware Marketing Partner?
PS: Most regenerative medicine clinics fail compliance reviews not because they are trying to cut corners but because the rules live in three separate places: federal FDA, federal FTC, and state-specific statutes. Missing the state layer is the most common failure point we see.
Regen Portal builds marketing programs with all three layers built into the review process. Reach out at hello@regenportal.com.
For more on me, subscribe to the Regen Portal YouTube channel: https://www.youtube.com/@oatellez
State rules stack on top of federal ones rather than replacing them, which is where multi-state practices get caught. Our marketing compliance work accounts for both, alongside your counsel.
About Regen Portal
Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
About the Author
Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
